MEASLES VACCINE DEVELOPMENT IN RHESUS MONKEY

恒河猴麻疹疫苗的开发

• 批准号: 7715552
• 负责人: Michael B. McChesney
• 金额: $ 8.13万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7715552
• 关键词: Age-Months; Attenuated; Computer Retrieval of Information on Scientific Projects Database; DNA Vaccines; Disease; Funding; Grant; Infection; Institution; Life; Macaca mulatta; Maternal antibody; Measles; Measles Vaccine; Measles virus; Mutation; Newborn Infant; Nucleoproteins; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Viral; prevent; vaccine development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: The live, attenuated measles vaccine is very effective, although maternal antibody prevents its administration prior to 6 months of age. We are investigating the ability of a DNA vaccine encoding the measles viral hemaglutinin, fusion and nucleoprotein to protect newborn infants from measles. We are also attempting to define mutations in measles virus that result in attenuated infection and disease in the rhesus monkey.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 目的：尽管母体抗体会阻止在 6 个月大之前接种麻疹减毒活疫苗，但麻疹减毒活疫苗非常有效。我们正在研究编码麻疹病毒血凝素、融合蛋白和核蛋白的 DNA 疫苗保护新生儿免受麻疹感染的能力。 我们还试图确定麻疹病毒的突变，这些突变会导致恒河猴的感染和疾病减弱。